Table 2.
Comparison of outcomes
| Outcome | Valuea |
|||||
|---|---|---|---|---|---|---|
| Unadjusted model |
Propensity score-matched analysis |
|||||
| Oral ribavirin therapy (n = 114) | Non-ribavirin therapy (n = 31) | P value | Oral ribavirin treatment (n = 21) | Non-ribavirin therapy (n = 21) | P value | |
| Adverse effects of treatment | NA | NA | ||||
| Hemolytic anemia | 4 | NA | 1 | NA | ||
| Nephrotoxicity | 2 | NA | 0 | NA | ||
| Drug rash | 1 | NA | 0 | NA | ||
| Length of hospital stay after viral infection, median days (IQR) | 20 (11–39) | 10 (4–23) | 0.002 | 13 (10–25) | 11 (4–25) | 0.49 |
| 7-day mortality | 6 (5) | 4 (13) | 0.14 | 1 (5) | 4 (19) | 0.34 |
| 14-day mortality | 11 (10) | 5 (16) | 0.34 | 1 (5) | 4 (19) | 0.34 |
| 30-day mortality | 35 (31) | 6 (19) | 0.21 | 5 (24) | 4 (19) | 0.71 |
| Underlying respiratory death | 14 (12) | 5 (16) | 0.56 | 3 (14) | 4 (19) | >0.99 |
| Subgroup analysis for 30-day mortalityb | ||||||
| Upper respiratory infection | 5/37 (14) | 1/11 (9) | >0.99 | 0 | 0 | NA |
| Lower respiratory infection | 30/77 (39) | 5/20 (25) | 0.27 | 5/16 (31) | 4/13 (30) | >0.99c |
| Pneumonia severity index | ||||||
| Risk classes I–III | 12/56 (21) | 3/16 (19) | >0.99 | 0 | 2/12 (17) | 0.48c |
| Risk classes IV–V | 23/58 (39) | 3/15 (20) | 0.29 | 5/10 (50) | 2/9 (22) | 0.35c |
| With coinfection | 21/44 (48) | 4/9 (44) | >0.99 | 4/9 (44) | 3/5 (60) | >0.99c |
| Without coinfection | 14/70 (20) | 2/22 (9) | 0.34 | 1/12 (8) | 1/16 (6) | >0.99c |
| HSCT recipient | 20/58 (34) | 5/16 (31) | 0.81 | 1/9 (11) | 3/10 (30) | 0.58c |
a
Data are presented as numbers (%) of patients unless otherwise specified.
b
Subgroup analysis was conducted for 30-day mortality of each group.
c
Fisher exact test or Pearson χ2 test.